84 related articles for article (PubMed ID: 28779995)
1. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
3. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
4. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
5. RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Carvajal-Carmona LG; Tomlinson I; Sahasrabudhe R
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27154966
[No Abstract] [Full Text] [Related]
6. HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Pinheiro M; Drigo SA; Tonhosolo R; Andrade SCS; Marchi FA; Jurisica I; Kowalski LP; Achatz MI; Rogatto SR
Oncotarget; 2017 Jun; 8(25):40896-40905. PubMed ID: 28402931
[TBL] [Abstract][Full Text] [Related]
7. G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.
Ruiz-Ferrer M; Fernández RM; Navarro E; Antiñolo G; Borrego S
Thyroid; 2016 Jul; 26(7):987-8. PubMed ID: 27245704
[No Abstract] [Full Text] [Related]
8. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
9. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
10. Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma.
de Carlos Artajo J; Irigaray Echarri A; García Torres J; Pineda Arribas JJ; Ernaga Lorea A; Eguílaz Esparza N; Zubiría Gortázar JM; Anda Apiñániz E
Endocrinol Diabetes Nutr (Engl Ed); 2022 Apr; 69(4):262-270. PubMed ID: 35353680
[TBL] [Abstract][Full Text] [Related]
11. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
12. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
Cirello V
Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
[TBL] [Abstract][Full Text] [Related]
13. Is Familial Nonmedullary Thyroid Cancer A More Aggressive Type of Thyroid Cancer?
Muallem Kalmovich L; Jabarin B; Koren S; Or K; Marcus E; Tkacheva I; Benbassat C; Steinschneider M
Laryngoscope; 2021 Feb; 131(2):E677-E681. PubMed ID: 32761812
[TBL] [Abstract][Full Text] [Related]
14. Familial non-medullary thyroid cancer: a critical review.
Capezzone M; Robenshtok E; Cantara S; Castagna MG
J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
[TBL] [Abstract][Full Text] [Related]
15. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
16. The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.
Bohórquez ME; Estrada AP; Stultz J; Sahasrabudhe R; Williamson J; Lott P; Duque CS; Donado J; Mateus G; Bolaños F; Vélez A; Echeverry M; Carvajal-Carmona LG
Endocr Connect; 2016 May; 5(3):123-7. PubMed ID: 27097599
[TBL] [Abstract][Full Text] [Related]
17. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
[TBL] [Abstract][Full Text] [Related]
18. Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members.
Capezzone M; Sagnella A; Pilli T; Maino F; Forleo R; Cantara S; Cartocci A; Castagna MG
J Clin Endocrinol Metab; 2021 Jan; 106(2):e855-e865. PubMed ID: 33175120
[TBL] [Abstract][Full Text] [Related]
19. Germ-line mutations in
Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
[TBL] [Abstract][Full Text] [Related]
20. Identification of NID1 as a novel candidate susceptibility gene for familial non-medullary thyroid carcinoma using whole-exome sequencing.
de Mello LEB; Carneiro TNR; Araujo AN; Alves CX; Galante PAF; Buzatto VC; das Graças de Almeida M; Vermeulen-Serpa KM; de Lima Vale SH; José de Pinto Paiva F; Brandão-Neto J; Cerutti JM
Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34941562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
